Clinical Trials
Below, please find a listing of VentiRx Pharmaceuticals’ clinical trials and links to additional trial protocol information for these studies as posted on the National Institutes of Health (NIH) clinical trials website (www.clinicaltrials.gov). For general information on clinical trials, terms related to clinical trials and other general health information, please visit the NIH website.
A Phase 2 randomized, double-blind, placebo-controlled trial evaluating VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer. The primary objective is to compare the overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone.
More information about this ongoing trial can be found at clinicaltrials.gov.
A Phase I trial to evaluate the safety and dose best dose of VTX-2337 and liposomal doxorubicin hydrochloride in patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer.
More information about this ongoing trial can be found at clinicaltrials.gov.
A Phase I trial to evaluate the safety and best dose of TLR8 agonist VTX-2337 when given together with cetuximab in patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck (SCCHN).
More information about this ongoing trial can be found at clinicaltrials.gov.